Antiretroviral Treatment Interruptions Induced by the Kenyan Postelection Crisis Are Associated with Virological Failure

Overview

Journal J Acquir Immune Defic Syndr

Specialty Infectious Diseases

Date 2013 Sep 20

PMID 24047971

Citations 17

Authors

Marita Mann

Lameck Diero

Emmanuel Kemboi

Fidelis Mambo

Mary Rono

Wilfred Injera

Allison DeLong

Leeann Schreier

Kara W Kaloustian

John Sidle

Nathan Buziba

Rami Kantor

Affiliations

Soon will be listed here.

Abstract

Background: Antiretroviral treatment interruptions (TIs) cause suboptimal clinical outcomes. Data on TIs during social disruption are limited.

Methods: We determined effects of unplanned TIs after the 2007-2008 Kenyan postelection violence on virological failure, comparing viral load (VL) outcomes in HIV-infected adults with and without conflict-induced TI.

Results: Two hundred and one patients were enrolled, median 2.2 years after conflict and 4.3 years on treatment. Eighty-eight patients experienced conflict-related TIs and 113 received continuous treatment. After adjusting for preconflict CD4, patients with TIs were more likely to have detectable VL, VL >5,000 and VL >10,000.

Conclusions: Unplanned conflict-related TIs are associated with increased likelihood of virological failure.

Citing Articles

Outcome of HIV patients on ART during the war and siege in a tertiary hospital in Northern Ethiopia: a cross-sectional study.

Weledegebriel M, Nigusse A, Gebru T, Haftu H, Gebrehiwet T, Tsegay N Sci Rep. 2025; 15(1):6434.

PMID: 39984629 PMC: 11845719. DOI: 10.1038/s41598-025-90848-w.

Factors associated with ART interruption during the COVID-19 crisis in Burundi (the EPIC community-based research program).

Niyongabo A, Villes V, Diagne R, Castro Avila J, Mutima J, Gakima D Sci Rep. 2024; 14(1):13187.

PMID: 38851798 PMC: 11162476. DOI: 10.1038/s41598-024-63805-2.

Associations of inter-annual rainfall decreases with subsequent HIV outcomes for persons with HIV on antiretroviral therapy in Southern Africa: a collaborative analysis of cohort studies.

Trickey A, Johnson L, Fung F, Bonifacio R, Iwuji C, Biraro S BMC Infect Dis. 2023; 23(1):889.

PMID: 38114912 PMC: 10731689. DOI: 10.1186/s12879-023-08902-9.

Effects of the COVID-19 pandemic on late postpartum women living with HIV in Kenya.

Humphrey J, Alera M, Enane L, Kipchumba B, Goodrich S, Scanlon M PLOS Glob Public Health. 2023; 3(3):e0001513.

PMID: 36989321 PMC: 10058168. DOI: 10.1371/journal.pgph.0001513.

Peer-Led Community-Based Support Services and HIV Treatment Outcomes Among People Living With HIV in Wuxi, China: Propensity Score-Matched Analysis of Surveillance Data From 2006 to 2021.

Meng X, Yin H, Ma W, Gu J, Lu Z, Fitzpatrick T JMIR Public Health Surveill. 2023; 9:e43635.

PMID: 36961492 PMC: 10131765. DOI: 10.2196/43635.

References

Taylor S, Boffito M, Khoo S, Smit E, Back D . Stopping antiretroviral therapy. AIDS. 2007; 21(13):1673-82. DOI: 10.1097/QAD.0b013e3281c61394. View

Kaufmann G, Elzi L, Weber R, Furrer H, Giulieri S, Vernazza P . Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS. 2011; 25(4):441-51. DOI: 10.1097/QAD.0b013e3283430013. View

Ribaudo H, Haas D, Tierney C, Kim R, Wilkinson G, Gulick R . Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis. 2006; 42(3):401-7. DOI: 10.1086/499364. View

Luebbert J, Tweya H, Phiri S, Chaweza T, Mwafilaso J, Hosseinipour M . Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi. Clin Infect Dis. 2012; 55(3):441-8. DOI: 10.1093/cid/cis438. View

Betsi N, Koudou B, Cisse G, Tschannen A, Pignol A, Ouattara Y . Effect of an armed conflict on human resources and health systems in Côte d'Ivoire: prevention of and care for people with HIV/AIDS. AIDS Care. 2006; 18(4):356-65. DOI: 10.1080/09540120500200856. View

Kantor R, Diero L, DeLong A, Kamle L, Muyonga S, Mambo F . Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009; 49(3):454-62. PMC: 4859427. DOI: 10.1086/600396. View

Parienti J, Das-Douglas M, Massari V, Guzman D, Deeks S, Verdon R . Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008; 3(7):e2783. PMC: 2467488. DOI: 10.1371/journal.pone.0002783. View

Wolf E, Hoffmann C, Procaccianti M, Mosthaf F, Gersbacher E, Ulmer A . Long-term consequences of treatment interruptions in chronically HIV-1-infected patients. Eur J Med Res. 2005; 10(2):56-62. View

Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N . Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med. 2007; 8(2):96-104. DOI: 10.1111/j.1468-1293.2007.00436.x. View

10.

Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A . Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis. 2005; 40(5):728-34. DOI: 10.1086/427878. View

11.

Hirschel B, Flanigan T . Is it smart to continue to study treatment interruptions?. AIDS. 2009; 23(7):757-9. DOI: 10.1097/QAD.0b013e328321b791. View

12.

Delong A, Wu M, Bennett D, Parkin N, Wu Z, Hogan J . Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase. AIDS Res Hum Retroviruses. 2011; 28(8):894-901. PMC: 3399557. DOI: 10.1089/aid.2011.0120. View

13.

Graham S, Jalalian-Lechak Z, Shafi J, Chohan V, Deya R, Jaoko W . Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA. J Acquir Immune Defic Syndr. 2012; 60(5):511-8. PMC: 3404237. DOI: 10.1097/QAI.0b013e31825bd703. View

14.

Johnson V, Calvez V, Gunthard H, Paredes R, Pillay D, Shafer R . 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011; 19(4):156-64. PMC: 6148877. View

15.

Yoder R, Nyandiko W, Vreeman R, Ayaya S, Gisore P, Braitstein P . Long-term impact of the Kenya postelection crisis on clinic attendance and medication adherence for HIV-infected children in western Kenya. J Acquir Immune Defic Syndr. 2011; 59(2):199-206. DOI: 10.1097/QAI.0b013e31823b4448. View

16.

Mann M, Lurie M, Kimaiyo S, Kantor R . Effects of political conflict-induced treatment interruptions on HIV drug resistance. AIDS Rev. 2013; 15(1):15-24. PMC: 3774601. View

17.

Bangsberg D, Kroetz D, Deeks S . Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007; 4(2):65-72. DOI: 10.1007/s11904-007-0010-0. View

18.

Vreeman R, Nyandiko W, Sang E, Musick B, Braitstein P, Wiehe S . Impact of the Kenya post-election crisis on clinic attendance and medication adherence for HIV-infected children in western Kenya. Confl Health. 2009; 3:5. PMC: 2670263. DOI: 10.1186/1752-1505-3-5. View

19.

Ncaca L, Kranzer K, Orrell C . Treatment interruption and variation in tablet taking behaviour result in viral failure: a case-control study from Cape Town, South Africa. PLoS One. 2011; 6(8):e23088. PMC: 3152560. DOI: 10.1371/journal.pone.0023088. View

20.

Darwich L, Esteve A, Ruiz L, Bellido R, Clotet B, Martinez-Picado J . Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption. Antivir Ther. 2008; 13(7):945-51. View